Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.40 |
| ▸ | HTR2A | P28223 | 7/20 | 0.40 |
| ▸ | HTR2B | P41595 | 6/20 | 0.40 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.36 |
| ▸ | HTR1D | P28221 | 2/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3804505 | 0.90 | HTR2C (0.41) | HTR2CHTR2AHTR2BHTR1ATAAR1 | |
| SCHEMBL3791251 | 0.88 | HTR6 (0.41) | HTR2CHTR2AHTR2BHTR1ATAAR1 | |
| SCHEMBL3806730 | 0.87 | HTR2C (0.43) | HTR2CHTR2AHTR2BHTR1ATAAR1 | |
| SCHEMBL3804057 | 0.85 | HTR1A (0.46) | HTR2CHTR2AHTR2BHTR1ATAAR1 | |
| SCHEMBL1163485 | 0.82 | HTR2A (0.50) | HTR2CHTR2AHTR2BTAAR1HTR6 | |
| SCHEMBL17150095 | 0.82 | HTR1A (0.38) | HTR2CHTR2AHTR2BHTR1ATAAR1 | |
| SCHEMBL25747462 | 0.82 | HTR2C (0.34) | HTR2CHTR2AHTR2BHTR1ATAAR1 | |
| SCHEMBL13592771 | 0.81 | HTR2C (0.49) | HTR2CHTR2AHTR2BHTR1ATAAR1 | |
| Hydrochloric Acid SCHEMBL4394176 | 0.80 | HTR2C (0.48) | HTR2CHTR2AHTR2BHTR1ATAAR1 | |
| SCHEMBL3805002 | 0.80 | HTR6 (0.42) | HTR2CHTR2AHTR2BHTR1ATAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2254865-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | ORGANIX, INC. (US) | 2010-12-01 | — | — | EP | disclosed |
| US-20090318527-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-24 | — | — | US | disclosed |
| US-20090318527-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-24 | — | — | US | disclosed |
| WO-2009102805-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | ORGANIX INC. (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318527-A1 | INDOLE COMPOUNDS AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | HTR2C 30/4885HTR2A 27/4885HTR2B 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.